Daiichi Sankyo and AstraZeneca have received priority review from the US Food and Drug Administration (FDA) for the supplemental biologics licence application (sBLA) of Enhertu (fam-trastuzumab ...

This is Okuzawa. Thank you for taking time out of your busy schedule to attend Daiichi Sankyo's Financial Results Presentation today. Now, I will explain the consolidated financial results for the ...

GHENT, Belgium—Aikido Security has announced the acquisition of AI-native penetration testing platform developers Allseek and Haicker. Together, they are transforming weeks-long pen tests into ...

At least 187 code packages made available through the JavaScript repository NPM have been infected with a self-replicating worm that steals credentials from developers and publishes those secrets on ...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) for breast cancer – Enhertu – which is tipped to become a multibillion-dollar ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will receive ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, ...

Aikido Security Ltd. today disclosed what is being described as the largest npm supply chain compromise to date, after attackers injected malware into 18 popular packages that together account for ...

At least 18 popular JavaScript code packages that are collectively downloaded more than two billion times each week were briefly compromised with malicious software today, after a developer involved ...